eli lilly

This weekend's Barron's cover story discusses ways to play the space race as the industry flourishes. Other featured articles offer sensible stocks for a strange market, check on how biotechs with recent initial public offerings have fared and recommend bank stocks for income investors....

This weekend's Barron's cover story discusses a coming Alzheimer's crisis. Other featured articles discuss whether utilities are worth another look, which real estate investment trusts to focus on and how to play rising platinum prices. Also, the prospects for a popular trading app...

Benzinga has examined the prospects for many investor favorite stocks over the past week. The week's bullish calls included aerospace, automaker and pharmaceutical giants. A leading semiconductor maker and a struggling retailer were among the bearish calls. In a week when much of the nation...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included the iPhone maker and the leading electric vehicle maker. Bearish calls included entertainment, financial and pharmaceutical giants. The economic and social fallout from the...

Benzinga has featured a look at many investor favorite stocks over the past week. Bullish calls featured the iPhone maker and the world's largest retailer. Bearish calls included an iconic conglomerate and a pharma giant. The markets again are hitting new all-time highs, even with...

The Dow Jones Industrial Average hitting 20,000 was no fluke, according to the latest Barron's cover story, as current stock prices are well supported by corporate earnings and economic growth. Unless the new administration stumbles into a trade war, the Dow could overtake the 30,000...

Investors appear to be pleased with Eli Lilly and Co (NYSE: LLY)'s business after the company updated the investment community with short- and longer-term guidance. Eli Lilly's stock gained more than 5 percent on Thursday and was trading higher by another 1.50 percent at $72.45 ahead of Friday's...

Shares of Eli Lilly and Co (NYSE: LLY) gained more than 3 percent ahead of Thursday's market open after the company provided the investment community with its financial guidance and an update to a new insulin product. Financial Guidance Eli Lilly guided its full year fiscal 2016 earnings...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...

Eli Lilly and Co (NYSE: LLY) detailed in a presentation to the investment community its outlook for new product launches through 2023. Eli Lilly said that it has the potential to launch a total of 20 new products in the 10-year period beginning in 2014 and extending through 2023. In addition, the...

The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...

Two of the so-called FANG stocks offered up disappointing quarterly results last week. The other two FANG stocks are on deck to share their latest results this week. Wall Street analysts continue to look for strong earnings growth from both of them. The so-called FANG stocks were the momentum...

Upcoming earnings highlights include the latest results from two automaker giants. Wall Street analysts are looking for strong earnings growth from both of them. However, estimates have been slipping for one and rising for the other. Expectations were already high for the latest earnings from...

Upcoming earnings highlights include the latest results from two old-school giants striving to improve their prospects. Wall Street analysts are looking for earnings growth from just one of them. However, both have handily bested earnings expectations in recent quarters. The new earnings season...